

RESEARCH

Open Access



# LncRNA-NEAT1 from the competing endogenous RNA network promotes cardioprotective efficacy of mesenchymal stem cell-derived exosomes induced by macrophage migration inhibitory factor via the miR-142-3p/FOXO1 signaling pathway

Hanbin Chen<sup>1†</sup>, Wenzheng Xia<sup>2†</sup> and Meng Hou<sup>1\*</sup>

## Abstract

**Aims:** Extracellular vesicles, especially exosomes, have emerged as key mediators of intercellular communication with the potential to improve cardiac function as part of cell-based therapies. We previously demonstrated that the cardioprotective factor, macrophage migration inhibitory factor (MIF), had an optimizing effect on mesenchymal stem cells (MSCs). The aim of this study was to determine the protective function of exosomes derived from MIF-pretreated MSCs in cardiomyocytes and to explore the underlying mechanisms.

**Methods and results:** Exosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosome<sup>MIF</sup>), and delivered to cardiomyocytes subjected to H<sub>2</sub>O<sub>2</sub> in vitro. Regulatory long non-coding RNAs (lncRNAs) activated by MIF pretreatment were explored using genomics approaches. Exosome<sup>MIF</sup> protected cardiomyocytes from H<sub>2</sub>O<sub>2</sub>-induced apoptosis. Mechanistically, we identified lncRNA-NEAT1 as a mediator of exosome<sup>MIF</sup> by regulating the expression of miR-142-3p and activating Forkhead class O1 (FOXO1). The cardioprotective effects of exosome<sup>MIF</sup> were consistently abrogated by depletion of lncRNA-NEAT1, by overexpression of miR-142-3p, or by FOXO1 silencing. Furthermore, exosome<sup>MIF</sup> inhibited H<sub>2</sub>O<sub>2</sub>-induced apoptosis through modulating oxidative stress.

**Conclusions:** Exosomes obtained from MIF-pretreated MSCs have a protective effect on cardiomyocytes. The lncRNA-NEAT1 functions as an anti-apoptotic molecule via competitive endogenous RNA activity towards miR-142-3p. lncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosome<sup>MIF</sup> in protecting cardiomyocytes from apoptosis.

**Keywords:** Mesenchymal stem cells, Exosome, MIF, Cardiomyocytes apoptosis, lncRNA-NEAT1/miR-142-3p/FOXO1 signaling pathway, Oxidative stress

\* Correspondence: [244517813@qq.com](mailto:244517813@qq.com)

<sup>†</sup>Hanbin Chen and Wenzheng Xia contributed equally to this work.

<sup>1</sup>Department of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, People's Republic of China

Full list of author information is available at the end of the article



## Introduction

According to the World Health Organization, cardiovascular diseases (CVDs) consist of a group of disorders associated with the disruption of cardiac function, and are still a major cause of morbidity and mortality in the world [1]. Since the first study reporting the ability of skeletal muscle to repair the heart in 1998, a spectrum of stem cells has been investigated for the treatment of CVDs [2, 3]. However, stem cell therapy poses several major challenges for researchers and clinicians, including poor engraftment and survival of the transplanted cells, the occurrence of ventricular arrhythmias, and the risk of tumor formation [4]. Optimizing options, including cell-free approaches, have since served as potential new therapeutic strategies that including the benefits of cell therapy, but eliminating the need for cell transplantation.

Macrophage migration inhibitory factor (MIF) is involved in multiple CVDs, including myocardial infarction [5]. MIF-knockout mice showed heart contractile dysfunction [6], and MIF deficiency overtly exacerbated abdominal aorta constriction-induced cardiac hypertrophy and contractile anomalies [7]. Furthermore, MIF pretreatment enhanced the therapeutic potential of mesenchymal stem cells (MSCs) [8], and exogenous MIF improved the paracrine effect of MSCs [9]. Given the potential therapeutic benefits of biomimetic exosomes compared with stem cells themselves, it is necessary to determine if MIF pretreatment could affect the functions of such MSC-derived exosomes.

Long non-coding RNAs (lncRNAs) are a novel class of transcripts > 200 nucleotides long with absent protein-coding potential, which regulate gene expression at the epigenetic, transcriptional, and post-transcriptional levels [10]. lncRNAs are emerging as important players in heart development, heart failure, cardiomyocyte hypertrophy, and atherosclerosis [11]. The lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) is an lncRNA localized to the nucleus, which has been demonstrated to act as an oncogene in various human cancers [12, 13]. Accumulating evidence indicates that NEAT1 serves a critical role in cell survival [14]. Furthermore, upregulation of NEAT1 contributes to treatment in doxorubicin-induced cardiac damage [15]. Exosomes can contribute to cell-to-cell communication and modulate cellular activities in recipient cells by transferring their contents, including lncRNAs, with important effects [16, 17]. However, despite the potentially important effects of lncRNAs in cells or exosomes, the impact of modulating the lncRNA component of exosomes to improve the therapeutic effect of MSC-derived exosomes remains to be explored.

Sirtuins are a family of deacetylases known to act on numerous cellular pathways [18], including the Forkhead class O (FOXO) pathway, which regulates the cellular

response to oxidative stress, with cardioprotective effects [19]. The FOXO family of transcription factors serves as the integration of growth factor signaling, oxidative stress, and inflammation [20], by regulating the expression of several antioxidant enzyme genes, including SOD [21]. MiR-142-3p has also been suggested to regulate FOXO function under oxidative stress conditions [22]. FOXO transcription factors are crucial to heart homeostasis [23], and FOXO1 critically determines cardiomyocyte apoptosis, left ventricular remodeling, and ischemic oxidative stress [24, 25].

In the present study, we investigated the ability of exosomes derived from MIF-pretreated MSCs (exosome<sup>MIF</sup>) to counteract cardiomyocyte apoptosis induced by H<sub>2</sub>O<sub>2</sub>, and examined the mechanisms responsible for their action.

## Materials and methods

### Cell culture and treatment

#### *Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes*

HiPSC-derived cardiomyocytes were obtained from Cellular Dynamics International (Madison, WI, USA) and plated and maintained according to the manufacturer's guidelines. The cells were plated on 10 µg/mL fibronectin medium (Invitrogen 33016-015, Carlsbad, CA, USA) as a support matrix for 48 h at 37 °C and 5% CO<sub>2</sub>. The maintenance medium was changed every 2 days.

#### *Normal human adipose-derived MSCs (ADMSCs)*

ADMSCs (ATCC®) were cultured at an early passage (passage 3) in Gibco DMEM-F12 Medium, according to the supplier's specifications, and incubated at 37 °C and 5% CO<sub>2</sub>. The medium was changed every 48 h. Cells were harvested using 0.05% Trypsin-EDTA (cat. number 25300-054; Gibco) at 37 °C and 5% CO<sub>2</sub> for 3 min, transferred to phosphate-buffered saline (PBS), and then centrifuged at 300×g for 5 min. The cells were then used for the respective experiments.

#### *MIF treatment*

For MSC MIF treatment, cells were cultured in medium containing 100 ng/mL recombinant MIF (R&D Systems) and incubated at 37 °C for 1 h before treatment and throughout the process, as reported previously [26].

#### *H<sub>2</sub>O<sub>2</sub> treatment*

H<sub>2</sub>O<sub>2</sub> reduces cardiomyocyte viability in a concentration-dependent manner. We therefore treated cells with 100 µM H<sub>2</sub>O<sub>2</sub> (Sigma-Aldrich, St. Louis, MO, USA) for 24 h to induce apoptosis, as reported previously [27].

### Isolation of exosomes from medium

Exosomes were isolated from the culture medium by gradient centrifugation, as reported previously [2, 28]. Following initial centrifugation for 30 min at 3000×g, cells and other debris were removed and the supernatant was harvested and centrifuged at 10,000×g for 30 min to remove microvesicles larger than exosomes. The supernatant was finally centrifuged at 110,000×g for 70 min. The isolation process was performed at 4 °C, and the exosomes were resuspended in PBS and stored at – 80 °C.

### Transmission electron microscopy (TEM)

TEM was performed according to a published protocol [29]. In brief, after immunoprecipitation, exosomes were stored in 1% paraformaldehyde, dehydrated via an ethanol series, and embedded in EPON. Sections (65 nm) were stained with uranyl acetate and Reynold's lead citrate and examined with a JEM-1400plus transmission electron microscope.

### Nanoparticle tracking analysis (NTA)

The number and size of the exosomes were measured directly using a Nanosight NS 300 system (NanoSight Technology, Malvern, UK) [30]. Exosomes were resuspended in PBS at a concentration of 5 µg/mL and further diluted 100- to 500-fold to achieve 20–100 objects per frame. Samples were injected manually into the sample chamber at ambient temperature. Each sample was configured with a 488-nm laser and a high-sensitivity camera, and monitored in triplicate at a camera setting of 13 with an acquisition time of 30 s and a detection threshold setting of 7. At least 200 completed tracks were analyzed per video. The data were finally analyzed using NTA analytical software (version 2.3).

### Western blot

Exosomes and cardiomyocytes were harvested, and total protein was extracted using RIPA solution. Protein samples were denatured, separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes. The membranes were blocked in 5% fat-free milk for 2 h at room temperature and then incubated with CD63 (ab59479, 1:750), CD81 (ab79559, 1:500), FOXO1 (ab39670, 1:500), and β-actin (ab179467, 1:1000) primary antibodies at 4 °C overnight. The membranes were further incubated with IgG-horseradish peroxidase goat anti-rabbit/mouse secondary antibody (ab7090/ab97040, 1:2000) for 2 h at room temperature. Signals were developed by enhanced chemiluminescence (Sigma-Aldrich). The stained protein bands were visualized using a Bio-Rad ChemiDoc XRS imaging system and analyzed using Quantity One software.

### Flow cytometric analysis of cell apoptosis

Apoptosis was determined by detecting phosphatidylserine exposure on the cell plasma membranes using an Annexin V-FITC Apoptosis Detection Kit, according to the manufacturer's protocol. Briefly, cells were harvested, washed in ice-cold PBS, resuspended in 300 µL binding buffer, and incubated with 5 µL Annexin V-fluorescein isothiocyanate (FITC) solution for 30 min at 4 °C in dark conditions, followed by further incubation in 5 µL propidium iodide for 5 min. The cells were then analyzed immediately by bivariate flow cytometry using a BD FACSCanto II equipped with BD FACSDiva Software (Becton-Dickinson, San Jose, CA, USA).

### Calculation of caspase 3/7 and 8 activities

Caspase 3/7 and 8 activities in cardiomyocytes were determined by enzyme-linked immunosorbent assay (ELISA), as described previously [31]. Briefly, caspase 3/7 and 8 activities in cell lysates were measured using a Cell Meter Caspase 3/7, 8 Activity Apoptosis Assay Kit (AAT Bio., Sunnyvale, CA, USA) according to the user's manual. Results were read at 520 nm in a microplate reader (Bio-Rad, Hercules, CA, USA) and expressed as fold change in activity compared with the control.

### Microarray analysis

Exosomes and cardiomyocytes were lysed immediately in 500 µL TRIzol (ThermoFisher Scientific, Waltham, MA, USA) and stored at – 80 °C before purification using a standard phenol–chloroform extraction protocol with an RNAqueous Micro Kit (ThermoFisher Scientific). The transcriptome was subjected to microarray analysis using an Affymetrix human array (ThermoFisher Scientific) and normalized based upon quantiles.

### Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNA was isolated from exosomes and cells using TRIzol (Ambion; ThermoFisher Scientific). cDNA was synthesized from 1 µg of total RNA using Superscript II reverse transcriptase, according to the manufacturer's protocol. RT-PCR was conducted as described previously [32]. The primer sets (Invitrogen) used are listed in Table 1.

### Small interfering (si) RNA transfection

LncRNA-NEAT1 expression in MSCs was knocked down using siRNAs, with a non-targeting siRNA as a negative control (Invitrogen). FOXO1 expression in cardiomyocytes was also knocked down by siRNAs. The procedures were conducted as described previously [9]. The target sequences are listed in Table 1. Transfection efficiency was detected by qRT-PCR and western blot.

**Table 1** Primer sequences

Genes	Sequences
LncRNA-NEAT1	F: 5'-GTACGCGGGCAGACTAACAC-3' R: 5'-TGCGTCTAGACACCACAACC-3'
U6	F: 5'-GCTTCGGCAGCACATATACTAAAAT-3' R: 5'-CGCTTCACGAATTTGCGTGTGCAT-3'
miR-142-3p	F: 5'-TGTAGTGTTTCTACTTTAT-3' R: 5'-GTCGTATCCAGTGCAGGG-3'
FOXO1	F: 5'-CAGCAAATCAAGTTATGGAGGA-3' R: 5'-TATCATTGTGGGGAGGAGAGTC-3'
GAPDH	F: 5'-TTGCCATCAATGACCCCTTCA-3' R: 5'-CGCCCCACTTGATT TGA-3'
siRNA-LncRNA-NEAT1	5'-GCCAUCAGCUUUGAAUAAAUU-3'
siRNA-LncRNA-NT	5'-UUCUCCGAA CGUGUCACGU-3'
siRNA-FOXO1	5'-CGGAGAAUGUAUACAAGCATT-3'
siRNA-NT	5'-GGAGUUAUGAGUCAGUAUATT-3'

### miR-142-3p overexpression

Cardiomyocytes were seeded into 6-well plates at a density of  $1 \times 10^5$  cells per well and incubated for 12 h. To induce overexpression of miR-142-3p, cells were transfected with miR-142-3p mimic or negative control (NC) mimic (Pre-miR™ miRNA Precursors, Life Technologies, Karlsruhe, Germany) using X-treme transfection reagent (Roche Applied Science, Penzberg, Germany), according to the manufacturer's protocol. The cells were harvested for further analysis 48 h after transfection, and the transfection efficiency was analyzed by qRT-PCR.

### Luciferase reporter assay

The 3'-untranslated regions (UTR) of lncRNA-NEAT1 and FOXO1 were synthesized, annealed, and inserted into the SacI and HindIII sites of the pmir-reporter luciferase vector (Ambion), downstream of the luciferase stop codon to induce mutagenesis of lncRNA-NEAT1 and FOXO1. The constructs were validated by sequencing. Cardiomyocytes were seeded into a 24-well plate for luciferase assay. After overnight culture, the cells were co-transfected with wild-type (WT) or mutated plasmid, and equal amounts of miR-142-3p mimic. Luciferase assays were performed using a Dual Luciferase Reporter Assay System (Promega) 24 h after transfection.

### Measurement of reactive oxygen species (ROS) production

Cells were detached from culture plates using 0.25% trypsin-EDTA, collected in 5 mL round-bottomed polystyrene tubes, and washed with  $1 \times$  Wash Buffer. The cell

suspension was centrifuged for 5 min at  $400 \times g$  at room temperature, and the supernatant was discarded. The cell pellet was resuspended in 500  $\mu$ L of ROS/Superoxide Detection Solution. The cells were then incubated for 30 min at 37 °C in the dark. Data were acquired using a FACScan (BD Biosciences) and analyzed using CellQuest software (BD Biosciences).

### Lipid peroxidation assay

Lipid peroxidation was measured using an assay kit (Abcam) to measure the formation of malondialdehyde (MDA), according to the manufacturer's instructions. Briefly, fibroblasts ( $1 \times 10^6$  cells) were homogenized on ice in 300  $\mu$ L of MDA lysis buffer (containing 3  $\mu$ L of 100 $\times$  butylated hydroxytoluene) and then centrifuged (13,000 $\times g$  for 10 min) to remove insoluble material. The supernatant (200  $\mu$ L) was added to 600  $\mu$ L of thio-barbituric acid and incubated at 95 °C for 60 min. Samples were then cooled to room temperature in an ice bath for 10 min, and the absorbance at 532 nm was measured using a spectrophotometer.

### Determination of 4-hydroxynonenal (4-HNE) levels

We evaluated 4-HNE levels using commercially available kits (Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer's instructions.

### Superoxide dismutase (SOD) activity

SOD activity in cells was determined using a colorimetric assay kit (Abcam), according to the manufacturer's instructions. Briefly, protein was isolated from the cells using lysis buffer and SOD activity was measured in 10  $\mu$ g of total protein extract. Absorbance was measured at 450 nm.


### Statistical analysis

Data are expressed as the mean  $\pm$  standard deviation (SD). Differences between groups were tested by one-way analysis of variance, and comparisons between two groups were evaluated using Student's *t* test. Analyses were performed using SPSS package v19.0 (SPSS Inc., Chicago, IL, USA).  $P < 0.05$  was considered statistically significant.

## Results

### Exosomes derived from MSCs pretreated with MIF protected cardiomyocytes from apoptosis

Given the innate cardioprotective effect of MIF, we determined if exosome<sup>MIF</sup> affected human cardiomyocyte survival. Exosomes isolated from MSCs exhibited a round morphology and size of 50–100 nm, according to TEM. Moreover, expression of the exosome markers CD63 and CD81 were confirmed by western blot (Fig. 1a–c). We also determined the effects of MIF-



conditioned exosomes on  $H_2O_2$ -induced cardiomyocyte apoptosis. Exosome<sup>MIF</sup> protected cardiomyocytes from  $H_2O_2$ -induced apoptosis, as measured by FACS (Fig. 1d, e), and reduced caspases 3/7 and caspase 8 activities (Fig. 1f, g). However, exosomes from untreated MSCs showed less cellular protection, indicating that the observed effects were MIF-specific.

#### Exosomal transfer of lncRNA-NEAT1 from MSCs to cardiomyocytes exerted cellular protection

We investigated the functional molecules responsible for the protective effect of exosome<sup>MIF</sup>. lncRNA expression levels in normal exosome and exosome<sup>MIF</sup> were analyzed by microarray. lncRNA-NEAT1 levels were increased in exosome<sup>MIF</sup>, as confirmed by qRT-




Fig. 2 (See legend on next page.)

(See figure on previous page.)

**Fig. 2** Exosomal transfer of lncRNA-NEAT1 from MSCs to cardiomyocytes and cytoprotective effect. **a** Heat map of lncRNAs differentially expressed between exosomes derived from MSCs pretreated with MIF (exosome<sup>MIF</sup>) and exosomes derived from untreated MSCs (exosome). **b** lncRNA-NEAT1 expression was validated by qRT-PCR in exosome<sup>MIF</sup> and exosome. \**P* < 0.05 vs. exosome. **c** lncRNA-NEAT1 mRNA was examined by qRT-PCR in cardiomyocytes incubated with exosome<sup>MIF</sup> or exosome. \**P* < 0.05 vs. exosome. MSCs were transfected with siRNA against lncRNA-NEAT1 or control siRNA-NT. **d** siRNA-mediated transfection efficiency was demonstrated by qRT-PCR. MSCs without treatment were used as a control. Each column represents mean ± SD of three independent experiments. \**P* < 0.05 vs. siRNA-lncRNA-NEAT1. **e, f** MSCs were transfected with siRNA against lncRNA-NEAT1 or control siRNA-NT and then treated with MIF, and the exosomes were collected and added to the cardiomyocytes. lncRNA-NEAT1 mRNA levels in exosomes and cardiomyocytes treated with the respective exosomes were examined by qRT-PCR. Exosomes derived from MSCs without treatment were used as a control. Cardiomyocytes without exosome treatment were used as a control. Each column represents mean ± SD of three independent experiments. \**P* < 0.05 vs. control; ▲*P* < 0.05 vs. MIF+siRNA-lncRNA-NEAT1. Exosomes derived from MSCs transfected with siRNA against lncRNA-NEAT1 or control siRNA-NT and treated with MIF, or with MIF alone, were added to H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes. **g, h** Apoptosis was analyzed by FACS. Activities of **i** caspases 3/7 and **j** caspase 8 in cell lysates were measured by ELISA. Each column represents mean ± SD of three independent experiments. \**P* < 0.05 vs. control; ▲*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>; °*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosome<sup>MIF+siRNA-lncRNA-NEAT1</sup>

PCR (Fig. 2a, b), and lncRNA-NEAT1 expression levels were also significantly increased in cardiomyocytes after incubation with exosome<sup>MIF</sup> (Fig. 2c). Silencing the expression of lncRNA-NEAT1 in MSCs by siRNA decreased its expression in MSCs, and in exosomes and cardiomyocytes treated with exosome<sup>MIF</sup>, as shown by qRT-PCR (Fig. 2d–f). Exosome<sup>MIF</sup> also protected cardiomyocytes from apoptosis, as measured by FACS (Fig. 2g, h), and reduced caspases 3/7 and caspase 8 activities (Fig. 2i, j). However, this protective effect was abolished by silencing lncRNA-NEAT1 in MSCs before treatment with MIF. These results suggest that exosomes derived from MIF-treated MSCs exerted their protective effect through direct lncRNA-NEAT1 transfer.

#### miR-142-3p modulated by exosomes was mediated by lncRNA-NEAT1

To determine the potential target of lncRNA-NEAT1-induced cardiomyocyte protection, we analyzed miR expression levels in H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes and H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes exposed to exosome<sup>MIF</sup> by microarray (Fig. 3a). H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes expressed higher levels of miR-142-3p, but miR-142-3p expression was substantially reduced in H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes with exosome<sup>MIF</sup>. However, the H<sub>2</sub>O<sub>2</sub>-induced increase in miR-142-3p was not alleviated by exosome<sup>MIF</sup> derived from MSCs with silenced lncRNA-NEAT1 (Fig. 3b). A search of the bioinformatics database (LncBase) suggested the existence of a putative binding site between lncRNA-NEAT1 and miR-142-3p (Fig. 3c), which was confirmed by dual-luciferase gene reporter assay. Relative luciferase activity was significantly weakened in the lncRNA-NEAT1-WT+miR-142-3p mimic group (Fig. 3d), suggesting that miR-142-3p is a direct target of lncRNA-NEAT1. We also determined if miR-142-3p might contribute to exosome<sup>MIF</sup>-induced cardioprotection. MiR-142-3p overexpression (Fig. 3e) markedly increased the apoptotic percentage, caspases 3/

7 and caspase 8 activities, even when exosome<sup>MIF</sup> was added into H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes (Fig. 3f–i).

#### Exosomal lncRNA-NEAT1/miR-142-3p protected cardiomyocytes through FOXO1 modulation

We investigated the target genes of miR-142-3p regulation using a bioinformatics database and identified a putative binding site between miR-142-3p and FOXO1 (Fig. 4a), which was confirmed by dual-luciferase gene reporter assay. Relative luciferase activity was significantly weakened in the FOXO1-WT+miR-142-3p mimic group (Fig. 4b). As expected, H<sub>2</sub>O<sub>2</sub> treatment markedly inhibited FOXO1 expression in cardiomyocytes, and this effect was attenuated by exosome<sup>MIF</sup>. In addition, overexpression of miR-142-3p impaired the expression of FOXO1 (Fig. 4c, d). These results suggested that FOXO1 was a target of miR-142-3p. We further investigated the mechanism underlying the modulation of FOXO1 by exosome<sup>MIF</sup> in H<sub>2</sub>O<sub>2</sub>-induced cellular apoptosis by silencing FOXO1 using siRNA. FOXO1 mRNA and protein expression levels were significantly reduced in cells transfected with siRNA-FOXO1 compared with cells transfected with non-targeting siRNA (siRNA-NT) as control (Fig. 4e–g). Exosome<sup>MIF</sup> protected cardiomyocytes from apoptosis (Fig. 5a, b) and decreased the activities of caspases 3/7 and caspase 8 (Fig. 5c, d). However, these effects were abolished by silencing FOXO1, but not by transfection with the control siRNA (Fig. 5a–d). These results demonstrated that FOXO1 was a putative direct target of miR-142-3p in the cardioprotective effect of exosome<sup>MIF</sup>.

#### Exosomes derived from MSCs pretreated with MIF modulated oxidant stress to rescue cardiomyocytes

Oxidative stress is related to cellular apoptosis. We therefore investigated the feedback loop between oxidative stress and the exosomal lncRNA-NEAT1/miR-142-3p/FOXO1 signaling pathway modulated by MIF. We examined ROS generation, lipid peroxidation, and SOD




Fig. 3 (See legend on next page.)



(See figure on previous page.)

**Fig. 3** miR-142-3p modulated by exosomes was mediated by lncRNA-NEAT1. **(a)** Heat map of miRNAs differentially regulated by exosome<sup>MIF</sup> in H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes. Red indicates up-regulation and blue indicates down-regulation. **(b)** qRT-PCR validation of differentially regulated miRNAs in H<sub>2</sub>O<sub>2</sub>-treated cardiomyocytes, with or without exosome<sup>MIF</sup> pre-treatment. MSCs were transfected with siRNA against lncRNA-NEAT1 or control siRNA-NT, followed by MIF. The exosomes were then collected and added to cardiomyocytes treated with H<sub>2</sub>O<sub>2</sub>. Cardiomyocytes without treatment were used as a control. \**P* < 0.05, versus control; ▲*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>; °*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosomes<sup>MIF+siRNA-lncRNA-NEAT1</sup>. **(c)** Binding sites of lncRNA and miRNA. **(d)** Binding of lncRNA and miRNA was verified by dual-luciferase reporter demonstrating that miR-142-3p was a target gene of lncRNA-NEAT1. \**P* < 0.05, compared with control group. Cardiomyocytes were transfected with a mimic control (miR-NC mimic) or miR-142-3p mimic, followed by exosome<sup>MIF</sup>, and then exposed to H<sub>2</sub>O<sub>2</sub>. Cardiomyocytes with or without exosome<sup>MIF</sup> were subjected to H<sub>2</sub>O<sub>2</sub>. Untreated cardiomyocytes were used as a control. **(e)** Transfection efficiency was analyzed by qRT-PCR. \**P* < 0.05 versus miR-142-3p mimic. **(f and g)** Apoptosis was analyzed by FACS. Activities of **(h)** caspases 3/7 and **(i)** caspase 8 in cell lysates were measured by ELISA. Each column represents mean ± SD of three independent experiments. \**P* < 0.05 vs. control; ▲*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>; °*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosome<sup>MIF</sup>+miR-142-3p mimic

activation. H<sub>2</sub>O<sub>2</sub> significantly increased ROS generation, MDA, and 4-HNE activation (Fig. 6a–d) and decreased SOD activation (Fig. 6e), while exosome<sup>MIF</sup> treatment decreased ROS generation, MDA, and 4-HNE activation (Fig. 6a–d) and increased SOD activation (Fig. 5e). These antioxidant effects of exosome<sup>MIF</sup> were abolished by silencing lncRNA-NEAT1, by ectopic expression of miR-142-3p, or by silencing FOXO1 (Fig. 6a–e).

## Discussion


Myocardial disease is a leading cause of morbidity and mortality in the world [33]. Due to the limited regenerative ability of the human heart following myocardial injury, stem cell-based therapies have served as a promising approach for improvement of cardiac repair and function [34, 35]. A spectrum of stem cells has been searched for treating myocardial disease, including skeletal myoblasts, bone marrow-derived cells, induced pluripotent stem cells, endothelial progenitor cells, and cardiac progenitor cells [2]. Researchers and clinicians are also researching alternative options, including cell-free approaches, a new candidate that possesses the benefit of cell therapy without the need for cell transplantation [36, 37]. MSCs appear to be a good candidate in light of their immunosuppressive properties and paracrine ability [38, 39].

MSCs are known to elevate heart function after cardiac damages [40], and their beneficial effects are partially mediated by paracrine factors by exosome transportation [41]. Exosomes comprise functional miRNAs and lncRNAs and serve as intercellular shuttles delivering important messages to affect the gene expression and cellular functions of distant organs [42, 43]. lncRNAs in exosomes were previously shown to be tissue-specific and stage-specific, but to also be modulated by the environment [44, 45]. The current study showed that among the potential cardioprotective lncRNAs, lncRNA-NEAT1 was highly expressed in exosomes derived from MSCs treated with MIF. Moreover, exosome<sup>MIF</sup> showed a better


anti-apoptotic effect than exosomes from untreated MSCs in cardiomyocytes subjected to H<sub>2</sub>O<sub>2</sub>. These results support the perspective that lncRNAs in exosomes are environment-specific [46, 47]. These characteristics of lncRNAs transmitted by exosomes make them good candidate therapeutic agents.

lncRNAs are distributed in both the nucleus and cytoplasm and regulate intracellular signaling pathways via different mechanisms, including chromatin modification, gene transcription regulation, and competing endogenous RNAs (ceRNAs) [48]. Among these, ceRNAs have a potentially important role in cardiac-related diseases [49, 50]. Recent studies revealed that cardiac hypertrophy-related factor regulated cardiac hypertrophy by targeting miR-489. The lncRNA for myocardial infarction-regulatory factor inhibited autophagy by modulating miR-26a [51]. The lncRNA-NEAT1 is a 2.1-kb lncRNA transcribed from the NEAT1 gene, constituting a nuclear body with multiple roles in gene expression [52]. NEAT1 is important for RNA stability [53]. MiR-142-3p was found to be inhibited by lncRNA-NEAT1 in the current study, and previous studies have reported multiple functions of miR-142-3p in CVD [54, 55]. Forced expression of miR-142 induced extensive apoptosis and cardiac dysfunction, while loss of miR-142 fully rescued cardiac function in a murine heart failure model [56]. In the present research, the lncRNA-NEAT1/miR-142-3p axis mediated the effect of exosome<sup>MIF</sup> in protecting cardiomyocytes from apoptosis. Furthermore, the protection of cardiomyocytes in vitro by exosome<sup>MIF</sup> was markedly abolished by silencing lncRNA-NEAT1 expression in MSCs or by miR-142-3p overexpression in cardiomyocytes. These support the important role of exosomal lncRNA-NEAT1/miR-142-3p targeting in exosome<sup>MIF</sup>-mediated cardiovascular protection.

The FOXO1 transcription factor plays a role in cardiac metabolic flexibility and cell survival [57]. FOXO1 was previously shown to be a pivotal factor in cardiac autophagy, and restored FOXO1-related autophagy




**Fig. 4** FOXO1 was a direct target of miR-142-3p. **a** Predicted binding sites between miR-142-3p and the FOXO1 3'-UTR. **b** Dual-luciferase assay was performed in cardiomyocytes after co-transfection with FOXO1 3'-UTR WT or mutant (MUT) plasmids, and miR-142-3p mimics. \**P* < 0.05 vs. control in the WT group. **c, d** Western blot analysis of FOXO1 and β-actin protein levels in cardiomyocytes transfected with mimic control or miR-142-3p mimic treated with the exosome<sup>MIF</sup>, and subjected to H<sub>2</sub>O<sub>2</sub>. Cardiomyocytes with or without exosome<sup>MIF</sup> were subjected to H<sub>2</sub>O<sub>2</sub>. Untreated cardiomyocytes were used as a control. \**P* < 0.05 vs. control; ▲*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>; °*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosome<sup>MIF</sup> miR-142-3p mimic. **e-g** Cardiomyocytes were transfected with siRNA-FOXO1 or siRNA-NT. Untreated cardiomyocytes were used as a control. siRNA-mediated transfection efficiency was determined by qRT-PCR (**e**) and western blotting (**f, g**). Each column represents mean ± SD from three independent experiments. \**P* < 0.05 vs. siRNA-FOXO1



protected against cardiac aging and recovered mitochondrial integrity [58]. Modest FOXO1 overexpression was recently shown to be cardioprotective, by maintaining cardiac proteostasis and ameliorating age-associated functional decline [59]. Consistent with these findings, the present study showed that exosome<sup>MIF</sup> enhanced FOXO1 activity in cardiomyocytes via lncRNA-NEAT1/miR-142-3p to exert its cytoprotective effect.

Previous studies have suggested many complex molecular events resulting in the progression of cardiac damage [60]. Among these causes, oxidative stress and the associated inflammatory responses are likely to be the major signaling cascades causing cardiac damage

[61]. Cardiac infarction leads to a significant decrease in the levels of antioxidant enzymes such as SOD, and an increase in 4-HNE adducts, resulting in cardiomyocyte apoptosis [62, 63]. lncRNA-NEAT1 was recently shown to be involved in a protective mechanism against neuronal injury through modulating oxidative stress [64]. The activation of FOXO transcription factors in response to oxidative stress can induce a wide range of genes that regulate cellular responses such as resistance to cellular apoptosis [21]. Our current results showed that exosome<sup>MIF</sup> treatment attenuated oxidative stress through regulating the expression of several antioxidant enzyme genes, including SOD, to induce the ROS



(See figure on previous page.)

**Fig. 6** Exosomes derived from MSCs pretreated with MIF modulated oxidant stress to rescue cardiomyocytes. MSCs were transfected with siRNA against lncRNA-NEAT1 or control siRNA-NT and then treated with MIF. The exosomes were collected and added to cardiomyocytes treated with H<sub>2</sub>O<sub>2</sub>. Cardiomyocytes were transfected with miR-142-3p mimic, miR-NC mimic, siRNA-FOXO1, or siRNA-NT; treated with exosome<sup>MIF</sup>; and subjected to H<sub>2</sub>O<sub>2</sub>. Cardiomyocytes, with or without exosome<sup>MIF</sup>, were subjected to H<sub>2</sub>O<sub>2</sub>. Untreated cardiomyocytes were used as a control. **a, b** Intracellular ROS production was tested using a ROS detection kit and analyzed using flow cytometry. **c** Lipid peroxidation was evaluated by MDA formation. **d** Quantification of 4-HNE levels. **e** SOD activity was evaluated by colorimetric assay. \**P* < 0.05 vs. control; ▲*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>; °*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosome<sup>MIF+siRNA-lncRNA-NEAT1</sup>; □*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosome<sup>MIF</sup>+ miR-142-3p mimic; •*P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub>+exosome<sup>MIF</sup>+siRNA-FOXO1

scavenging process, while silencing lncRNA-NEAT1, miR-142-3p overexpression, or siRNA-FOXO1 abolished the antioxidant effect of exosome<sup>MIF</sup> treatment.

## Conclusion

The present study demonstrated that exosomes derived from MIF-treated MSCs prevented H<sub>2</sub>O<sub>2</sub>-induced cardiomyocyte apoptosis, and that these beneficial effects were mediated by the novel exosome/lncRNA-NEAT1/miR-142-3p/FOXO1 pathway. These results therefore identified a novel ceRNA signaling pathway to optimize stem cell-based cardioprotective functions. Given that exosomes are easy to obtain, exosome-mediated therapy represents a potentially useful approach for clinical applications.

## Abbreviations

MIF: Macrophage migration inhibitory factor; MSCs: Mesenchymal stem cells; lncRNAs: Long non-coding RNAs; miR: MicroRNA; CVDs: Cardiovascular diseases; FOXO1: Forkhead class O 1; hiPSC: Human-induced pluripotent stem cell; hADMSCs: Human adipose-derived MSCs; TEM: Transmission electron microscopy; NTA: Nanoparticle tracking analysis; qRT-PCR: Quantitative reverse transcription-polymerase chain reaction; siRNA: Small interfering RNA; ROS: Reactive oxygen species; MDA: Malondialdehyde; 4-HNE: 4-Hydroxynonenal; SOD: Superoxide dismutase

## Acknowledgements

Not applicable.

## Authors' contributions

HBC and WZX made substantial contributions to the data acquisition, analysis, and interpretation. MH was involved in the conception and design of the study and drafting the manuscript. All authors read and approved the final manuscript.

## Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81600278 to WZX), the Science and Technology Planning Project of Wenzhou (grant no. Y20190206 to HBC), and the Medical Science and Technology Project of Zhejiang Province (grant no. 2018KY517 to MH).

## Availability of data and materials

All data and materials are available in the manuscript.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup>Department of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, People's Republic of China. <sup>2</sup>Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.

Received: 20 November 2019 Revised: 23 December 2019

Accepted: 8 January 2020 Published online: 21 January 2020

## References

- WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Global health*. 2019;7:e1332–45.
- Adamiak M, Sahoo S. Exosomes in myocardial repair: advances and challenges in the development of next-generation therapeutics. *Mol Ther*. 2018;26:1635–43.
- Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. *Nat Med*. 1998;4:929–33.
- Cambria E, Pasqualini FS, Wolint P, Gunter J, Steiger J, Bopp A, Hoerstrup SP, Emmert MY. Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. *NPJ Regen Med*. 2017;2:17.
- Wang J, Tong C, Yan X, Yeung E, Gandavadi S, Hare AA, Du X, Chen Y, Xiong H, Ma C, Leng L, Young LH, Jorgensen WL, Li J, Bucala R. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. *Circulation*. 2013;128:225–36.
- Ma H, Wang J, Thomas DP, Tong C, Leng L, Wang W, Merk M, Zierow S, Bernhagen J, Ren J, Bucala R, Li J. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. *Circulation*. 2010;122:282–92.
- Xu X, Hua Y, Nair S, Bucala R, Ren J. Macrophage migration inhibitory factor deletion exacerbates pressure overload-induced cardiac hypertrophy through mitigating autophagy. *Hypertension*. 2014;63:490–9.
- Palumbo S, Tsai TL, Li WJ. Macrophage migration inhibitory factor regulates AKT signaling in hypoxic culture to modulate senescence of human mesenchymal stem cells. *Stem Cells Dev*. 2014;23:852–65.
- Xia W, Zhang F, Xie C, Jiang M, Hou M. Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells. *Stem Cell Res Ther*. 2015;6:82.
- Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. *Genetics*. 2013;193:651–69.
- Schonrock N, Harvey RP, Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. *Circ Res*. 2012;111:1349–62.
- Chakravarty D, Sboner A, Nair SS, Giannopoulos E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. *Nat Commun*. 2014;5:5383.
- Chen X, Kong J, Ma Z, Gao S, Feng X. Up regulation of the long non-coding RNA NEAT1 promotes esophageal squamous cell carcinoma cell progression and correlates with poor prognosis. *Am J Cancer Res*. 2015;5:2808–15.
- Choudhry H, Albukhari A, Morotti M, Haider S, Moralli D, Smythies J, Schodel J, Green CM, Camps C, Buffa F, Ratcliffe P, Ragoussis J, Harris AL, Mole DR. Tumor hypoxia induces nuclear paraspeckle formation through HIF-2alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival. *Oncogene*. 2015;34:4482–90.

15. Liu Y, Duan C, Liu W, Chen X, Wang Y, Liu X, Yue J, Yang J, Zhou X. Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity. *Arch Toxicol.* 2019;93:3261–76.
16. Atkinson SR, Marguerat S, Bitton DA, Rodriguez-Lopez M, Rallis C, Lemay JF, Cotobal C, Malecki M, Smialowski P, Mata J, Korber P, Bachand F, Bahler J. Long noncoding RNA repertoire and targeting by nuclear exosome, cytoplasmic exonuclease, and RNAi in fission yeast. *RNA.* 2018;24:1195–213.
17. Takahashi K, Yan IK, Haga H, Patel T. Modulation of hypoxia-signaling pathways by extracellular linc-RoR. *J Cell Sci.* 2014;127:1585–94.
18. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins—novel therapeutic targets to treat age-associated diseases. *Nat Rev Drug Discov.* 2008;7:841–53.
19. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ Res.* 2007;100:1512–21.
20. Hedrick SM, Hess Michelin R, Doedens AL, Goldrath AW, Stone EL. FOXO transcription factors throughout T cell biology. *Nat Rev Immunol.* 2012;12:649–61.
21. Storz P. Forkhead homeobox type O transcription factors in the responses to oxidative stress. *Antioxid Redox Signal.* 2011;14:593–605.
22. Martin-Alonso A, Cohen A, Quispe-Ricalde MA, Foronda P, Benito A, Berzosa P, Valladares B, Grau GE. Differentially expressed microRNAs in experimental cerebral malaria and their involvement in endocytosis, adherens junctions, FoxO and TGF-beta signalling pathways. *Sci Rep.* 2018;8:11277.
23. Hannenhalli S, Putt ME, Gilmore JM, Wang J, Parmacek MS, Epstein JA, Morrissey EE, Margulies KB, Cappola TP. Transcriptional genomics associates FOX transcription factors with human heart failure. *Circulation.* 2006;114:1269–76.
24. Li S, Zhu Z, Xue M, Yi X, Liang J, Niu C, Chen G, Shen Y, Zhang H, Zheng J, Zhao C, Liang Y, Cong W, Wang Y, Jin L. Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. *Biochim Biophys Acta Mol Basis Dis.* 2019;1865:1241–52.
25. Puthanveetil P, Wan A, Rodrigues B. FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival. *Cardiovasc Res.* 2013;97:393–403.
26. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. *J Biol Chem.* 2008;283:2784–92.
27. Gao W, Zhang C, Li W, Li H, Sang J, Zhao Q, Bo Y, Luo H, Zheng X, Lu Y, Shi Y, Yang D, Zhang R, Li Z, Cui J, Zhang Y, Niu M, Li J, Wu Z, Guo H, Xiang C, Wang J, Hou J, Zhang L, Thorne RF, Cui Y, Wu Y, Wen S, Wang B. Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. *Mol Ther.* 2019;27:365–79.
28. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 2007;9:654–9.
29. Muller L, Hong CS, Stolz DB, Watkins SC, Whiteside TL. Isolation of biologically-active exosomes from human plasma. *J Immunol Methods.* 2014;411:55–65.
30. Felicetti F, De Feo A, Coscia C, Puglisi R, Pedini F, Pasquini L, Bellenghi M, Errico MC, Pagani E, Care A. Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. *J Transl Med.* 2016;14:56.
31. Liu Y, Xiong Y, Xing F, Gao H, Wang X, He L, Ren C, Liu L, So KF, Jia X. Precise regulation of miR-210 is critical for the cellular homeostasis maintenance and transplantation efficacy enhancement of mesenchymal stem cells in acute liver failure therapy. *Cell Transplant.* 2017;26:805.
32. Moon J, Schwarz SC, Lee HS, Kang JM, Lee YE, Kim B, Sung MY, Hoglinger G, Wegner F, Kim JS, Chung HM, Chang SW, Cha KY, Kim KS, Schwarz J. Preclinical analysis of fetal human mesencephalic neural progenitor cell lines: characterization and safety in vitro and in vivo. *Stem Cells Transl Med.* 2017;6:576–88.
33. Asmarats L, Puri R, Latib A, Navia JL, Rodes-Cabau J. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. *J Am Coll Cardiol.* 2018;71:2935–56.
34. Protze SI, Lee JH, Keller GM. Human pluripotent stem cell-derived cardiovascular cells: from developmental biology to therapeutic applications. *Cell Stem Cell.* 2019;25:311–27.
35. Fiedler LR, Chapman K, Xie M, Maifoshie E, Jenkins M, Golfaroush PA, Bellahcene M, Nosedá M, Faust D, Jarvis A, Newton G, Paiva MA, Harada M, Stuckey DJ, Song W, Habib J, Narasimham P, Aqil R, Sanmugalingam D, Yan R, Pavanello L, Sano M, Wang SC, Sampson RD, Kanayaganam S, Taffet GE, Michael LH, Entman ML, Tan TH, Harding SE, Low CMR, Tralau-Stewart C, Perrier T, Schneider MD. MAP 4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo. *Cell Stem Cell.* 2019;24:579–91 e512.
36. de Couto G, Gallet R, Cambier L, Jaghatspanyan E, Makkar N, Dawkins JF, Berman BP, Marban E. Exosomal microRNA transfer into macrophages mediates cellular postconditioning. *Circulation.* 2017;136:200–14.
37. Milano G, Biemmi V, Lazzarini E, Balbi C, Ciullo A, Bolis S, Ameri P, Di Silvestre D, Mauri P, Barile L, Vassalli G. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. *Cardiovasc Res.* 2019. <https://doi.org/10.1093/cvr/cvz108>.
38. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, Timmers L, Lee CN, El Oakley RM, Pasterkamp G, de Kleijn DP, Lim SK. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. *Stem Cell Res.* 2010;4:214–22.
39. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. *Curr Mol Med.* 2012;12:574–91.
40. Ripa RS, Haack-Sorensen M, Wang Y, Jorgensen E, Mortensen S, Bindeslev L, Friis T, Kastrup J. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. *Circulation.* 2007;116:124–30.
41. Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. *Circ Res.* 2014;114:333–44.
42. Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, Gurlay EC, Liang G, Chen W, Lai G, Pandak WM, Robert Lippman H, Bajaj JS, Hylemon PB, Zhou H. Cholangiocyte-derived exosomal long noncoding rna H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. *Hepatology.* 2019;70:1317–35.
43. Cervio E, Barile L, Moccetti T, Vassalli G. Exosomes for intramyocardial intercellular communication. *Stem Cells Int.* 2015;2015:482171.
44. Huang P, Wang L, Li Q, Tian X, Xu J, Xu J, Xiong Y, Chen G, Qian H, Jin C, Yu Y, Cheng K, Qian L, Yang Y. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. *Cardiovasc Res.* 2019. <https://doi.org/10.1093/cvr/cvz139>.
45. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A, Prasanth KV. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. *PLoS Genet.* 2013;9:e1003368.
46. Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. *Trends Genet.* 2018;34:142–57.
47. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. *Nat Rev Genet.* 2016;17:47–62.
48. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci U S A.* 2009;106:11667–72.
49. Liu J, Li Y, Lin B, Sheng Y, Yang L. HBL1 is a human long noncoding RNA that modulates cardiomyocyte development from pluripotent stem cells by counteracting MIR1. *Dev Cell.* 2017;42:333–48 e335.
50. Cai B, Ma W, Ding F, Zhang L, Huang Q, Wang X, Hua B, Xu J, Li J, Bi C, Guo S, Yang F, Han Z, Li Y, Yan G, Yu Y, Bao Z, Yu M, Li F, Tian Y, Pan Z, Yang B. The long noncoding RNA CAREL controls cardiac regeneration. *J Am Coll Cardiol.* 2018;72:534–50.
51. Liang H, Su X, Wu Q, Shan H, Lv L, Yu T, Zhao X, Sun J, Yang R, Zhang L, Yan H, Zhou Y, Li X, Du Z, Shan H. LncRNA 2810403D21Rik/Mirf promotes ischemic myocardial injury by regulating autophagy through targeting Mir26a. *Autophagy.* 2019:1–15.
52. Wang Y, Hu SB, Wang MR, Yao RW, Wu D, Yang L, Chen LL. Genome-wide screening of NEAT1 regulators reveals cross-regulation between paraspeckles and mitochondria. *Nat Cell Biol.* 2018;20:1145–58.
53. Yamazaki T, Souquere S, Chujo T, Kobelke S, Chong YS, Fox AH, Bond CS, Nakagawa S, Pierron G, Hirose T. Functional domains of NEAT1 architectural lncRNA induce paraspeckle assembly through phase separation. *Mol Cell.* 2018;70:1038–53 e1037.
54. Sukma Dewi I, Celik S, Karlsson A, Hollander Z, Lam K, McManus JW, Tebbutt S, Ng R, Keown P, McMaster R, McManus B, Ohman J, Gidlof O. Exosomal

- miR-142-3p is increased during cardiac allograft rejection and augments vascular permeability through down-regulation of endothelial RAB11FIP2 expression. *Cardiovasc Res.* 2017;113:440–52.
55. Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, Iserin F, Rouvier P, Francois A, Vernerey D, Loyer X, Leprince P, Empana JP, Bruneval P, Loupy A, Jouven X. MicroRNAs as non-invasive biomarkers of heart transplant rejection. *Eur Heart J.* 2014;35:3194–202.
  56. Sharma S, Liu J, Wei J, Yuan H, Zhang T, Bishopric NH. Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. *EMBO Mol Med.* 2012;4:617–32.
  57. Bround MJ, Wambolt R, Luciani DS, Kulpa JE, Rodrigues B, Brownsey RW, Allard MF, Johnson JD. Cardiomyocyte ATP production, metabolic flexibility, and survival require calcium flux through cardiac ryanodine receptors in vivo. *J Biol Chem.* 2013;288:18975–86.
  58. Ren J, Yang L, Zhu L, Xu X, Ceylan AF, Guo W, Yang J, Zhang Y. Akt2 ablation prolongs life span and improves myocardial contractile function with adaptive cardiac remodeling: role of Sirt1-mediated autophagy regulation. *Aging Cell.* 2017;16:976–87.
  59. Blice-Baum AC, Zamboni AC, Kaushik G, Viswanathan MC, Engler AJ, Bodmer R, Cammarato A. Modest overexpression of FOXO maintains cardiac proteostasis and ameliorates age-associated functional decline. *Aging Cell.* 2017;16:93–103.
  60. Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular aging and heart failure: JACC review topic of the week. *J Am Coll Cardiol.* 2019;74:804–13.
  61. Niemann B, Rohrbach S, Miller MR, Newby DE, Fuster V, Kovacic JC. Oxidative stress and cardiovascular risk: obesity, diabetes, smoking, and pollution: part 3 of a 3-part series. *J Am Coll Cardiol.* 2017;70:230–51.
  62. Yan W, Guo Y, Tao L, Lau WB, Gan L, Yan Z, Guo R, Gao E, Wong GW, Koch WL, Wang Y, Ma XL. C1q/tumor necrosis factor-related protein-9 regulates the fate of implanted mesenchymal stem cells and mobilizes their protective effects against ischemic heart injury via multiple novel signaling pathways. *Circulation.* 2017;136:2162–77.
  63. Tanimoto T, Parseghian MH, Nakahara T, Kawai H, Narula N, Kim D, Nishimura R, Weisbart RH, Chan G, Richieri RA, Haider N, Chaudhry F, Reynolds GT, Billimek J, Blankenberg FG, Sengupta PP, Petrov AD, Akasaka T, Strauss HW, Narula J. Cardioprotective effects of HSP72 administration on ischemia-reperfusion injury. *J Am Coll Cardiol.* 2017;70:1479–92.
  64. Sunwoo JS, Lee ST, Im W, Lee M, Byun JI, Jung KH, Park KI, Jung KY, Lee SK, Chu K, Kim M. Altered expression of the long noncoding RNA NEAT1 in Huntington's disease. *Mol Neurobiol.* 2017;54:1577–86.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

